Genprex (GNPX) disclosed that it received notices of allowance for patents from both the U.S. and European Patent Offices for its Reqorsa® Gene Therapy in combination with PD-L1 and PD-1 antibodies, with patents expiring in 2037. This development supports Genprex’s Acclaim-3 clinical trial for small cell lung cancer, which has received FDA Fast Track and Orphan Drug Designations, potentially enhancing the company’s market position and stakeholder confidence.
More about Genprex
Genprex, Inc. operates in the biotechnology industry, focusing on developing gene therapies for cancer and diabetes. The company is known for its lead drug candidate, Reqorsa® Gene Therapy, which targets cancer treatment through innovative combinations with immunotherapy drugs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
